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Predicting mortality and progression in patients with con-
nective tissue disease-associated interstitial lung disease 
(CTD-ILD) is challenging because no accurate biomarker 
is existed and heterogeneity in disease and patient variables 
are extensive1. Idiopathic pulmonary fibrosis (IPF) is a poor 
prognostic and chronic fibrosing interstitial lung disease (ILD) 
of uncertain etiology. Previous studies have showed mortality 
risk prediction models in IPF including age, sex, and pulmo-
nary physiology scoring (GAP scoring system), and composite 
physiologic index (CPI) which are associated with mortality 
of IPF2-5. A prediction model in patients with CTD-ILD (ILD-
GAP) has been validated6. The Korean ILD Study Group in 
the Korean Academy of Tuberculosis and Respiratory Disease 
(KATRD) has created two IPF registries from 2003 to 2007 
as the 2008 group, and from 2013 to 2017 as the 2018 group. 
The Korean ILD study group has already showed that CPI and 
GAP models were associated with survival of IPF patients in a 
nationwide cohort study7-9.
Systemic sclerosis–associated interstitial lung disease (SSc-
ILD) is similar with IPF in many clinical features and prognos-
tic variables. Recently systematic approach to risk prediction 
in non-IPF chronic ILD (ILD-GAP)6 and CTD-ILD such as 
SSc-ILD10-13, rheumatoid arthritis (RA)-ILD14-16, and myositis-
associated (MA)-ILD17, and ILD with non-small cell lung can-
cer (NSCLC)18 has been conducted to date, and prognostica-
tion remains challenging for clinicians. These studies derived 
and validated the GAP and CPI models for risk prediction of 
the patients with IPF2. CPI, GAP, or ILD-GAP are applicable for 
evaluating the risk prediction of mortality and progression of 
patients with SSc-ILD, RA-ILD, and ILD-NSCLC in a similar 
manner as in those with IPF but the ILD-GAP risk prediction 
model is a poor predictor of mortality among individuals with 
MA-ILD17.
There are no valid biomarkers to predict the progression of 
SSc-ILD, although Anti-topoisomerase I and several inflam-
matory markers are candidate biomarkers that need further 
evaluation12. Despite the established relationship between 
SSc-ILD and morbidity and mortality, patients’ clinical courses 
are variable and difficult to predict. There is still no consensus 
on screening for ILD, nor on monitoring for disease progres-
sion. Currently chest computed tomography (CT) scans re-
main the gold standard to screen for and diagnose SSc-ILD12.
In clinical practice, the severity of SSc-ILD may be staged 
based on the “Goh criteria,” whereby patients have “limited” or 
“extensive” disease based on chest high-resolution CT scans 
with extent of ILD clearly less or more than 20% of involving 
pulmonary area, and with the use of an forced vital capacity 
(FVC) threshold of 70% in indeterminate cases19. A recent 
analysis showed that a decline in FVC or diffusing capacity for 
carbon monoxide (DLCO) over 2 years was a better predictor 
of mortality than baseline FVC and DLCO
20.
The progression of SSc-ILD is variable and it is important 
that patients are appropriately monitored after a diagnosis 
of ILD in SSc. Serial measurements of symptoms, physical 
examination, and pulmonary function tests (PFTs) are impor-
tant to assess disease progression at regular clinic visits, and 
recent studies highlight the impact of change in PFT on mor-
tality13,20,21. Kaenmuang and Navasakulpong13 reported that 
short-term lung function had declined during the 12-month 
follow-up in 78 patients with progressive or stable SSc-ILD. 
The predictive factors in progressive SSc-ILD were male sex 
and no previous aspirin treatment in a single Thailand univer-
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sity hospital of seventy-eight SSc-ILD.
In the recently published SENSCIS trial, patients with SSc-
ILD treated with nintedanib had a lower rate of annual FVC 
decline than those receiving placebo with difference of 41 
mL22. However, there is currently no consensus regarding 
treatment initiation or escalation. Most SSc experts make a 
decision on when to initiate therapy on a case-by-case basis 
according to their clinical experience and consideration of the 
risk factors for SSc-ILD progression. Better identification of 
which patients are at risk of progression will help to identify 
those who can benefit the most from early treatment23.
ILD is a major complication of SSc, and early and system-
atic screening of progression or deterioration is required and 
potentially enable treatment prior to deterioration of lung 
function in patients with SSc-ILD at high risk of disease pro-
gression is mandatory. Chest CT scans and serial PFTs remain 
important diagnostic tools, but may need to be performed 
regularly following SSc diagnosis to detect changes suggesting 
ILD12. In future, new imaging techniques and diagnostic and 
predictive biomarkers will play an important role in predicting 
mortality and progression of SSc-ILD.
Conflicts of Interest
No potential conflict of interest relevant to this article was 
not reported.
References
1. Winstone TA, Assayag D, Wilcox PG, Dunne JV, Hague CJ, 
Leipsic J, et al. Predictors of mortality and progression in 
scleroderma-associated interstitial lung disease: a systematic 
review. Chest 2014;146:422-36.
2. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, 
et al. A multidimensional index and staging system for idio-
pathic pulmonary fibrosis. Ann Intern Med 2012;156:684-91.
3. Wells AU, Desai SR, Rubens MB, Goh NS, Cramer D, Nich-
olson AG, et al. Idiopathic pulmonary fibrosis: a composite 
physiologic index derived from disease extent observed by 
computed tomography. Am J Respir Crit Care Med 2003; 
167:962-9.
4. du Bois RM, Weycker D, Albera C, Bradford WZ, Costabel U, 
Kartashov A, et al. Ascertainment of individual risk of mor-
tality for patients with idiopathic pulmonary fibrosis. Am J 
Respir Crit Care Med 2011;184:459-66.
5. du Bois RM, Albera C, Bradford WZ, Costabel U, Leff JA, 
Noble PW, et al. 6-Minute walk distance is an independent 
predictor of mortality in patients with idiopathic pulmonary 
fibrosis. Eur Respir J 2014;43:1421-9.
6. Ryerson CJ, Vittinghoff E, Ley B, Lee JS, Mooney JJ, Jones KD, 
et al. Predicting survival across chronic interstitial lung dis-
ease: the ILD-GAP model. Chest 2014;145:723-8.
7. Lee SH, Park JS, Kim SY, Kim DS, Kim YW, Chung MP, et al. 
Comparison of CPI and GAP models in patients with idio-
pathic pulmonary fibrosis: a nationwide cohort study. Sci Rep 
2018;8:4784.
8. Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. 
Predicting survival of patients with idiopathic pulmonary 
fibrosis using GAP score: a nationwide cohort study. Respir 
Res 2016;17:131.
9. Lee SH, Kim SY, Kim DS, Kim YW, Chung MP, Uh ST, et al. 
Comparisons of prognosis between surgically and clini-
cally diagnosed idiopathic pulmonary fibrosis using gap 
model: a Korean national cohort study. Medicine (Baltimore) 
2016;95:e3105.
10. Ryerson CJ, O’Connor D, Dunne JV, Schooley F, Hague CJ, 
Murphy D, et al. Predicting mortality in systemic sclerosis-
associated interstitial lung disease using risk prediction 
models derived from idiopathic pulmonary fibrosis. Chest 
2015;148:1268-75.
11. Wu W, Jordan S, Becker MO, Dobrota R, Maurer B, Fretheim 
H, et al. Prediction of progression of interstitial lung disease 
in patients with systemic sclerosis: the SPAR model. Ann 
Rheum Dis 2018;77:1326-32.
12. Distler O, Assassi S, Cottin V, Cutolo M, Danoff SK, Denton CP, 
et al. Predictors of progression in systemic sclerosis patients 
with interstitial lung disease. Eur Respir J 2020;55:1902026.
13. Kaenmuang P, Navasakulpong A. Short-term lung function 
changes and predictors of progressive systemic sclerosis-
related interstitial lung disease. Tuberc Respir Dis 2020 Jul 15 
[Epub]. https://doi.org/10.4046/trd.2020.0043.
14. Morisset J, Vittinghoff E, Lee BY, Tonelli R, Hu X, Elicker BM, 
et al. The performance of the GAP model in patients with 
rheumatoid arthritis associated interstitial lung disease. 
Respir Med 2017;127:51-6.
15. Nurmi HM, Purokivi MK, Karkkainen MS, Kettunen HP, 
Selander TA, Kaarteenaho RL. Are risk predicting models 
useful for estimating survival of patients with rheumatoid 
arthritis-associated interstitial lung disease? BMC Pulm Med 
2017;17:16.
16. Kim HC, Lee JS, Lee EY, Ha YJ, Chae EJ, Han M, et al. Risk pre-
diction model in rheumatoid arthritis-associated interstitial 
lung disease. Respirology 2020 May 22 [Epub]. https://doi.
org/10.1111/resp/13848.
17. Brusca RM, Pinal-Fernandez I, Psoter K, Paik JJ, Albayda J, 
Mecoli C, et al. The ILD-GAP risk prediction model performs 
poorly in myositis-associated interstitial lung disease. Respir 
Med 2019;150:63-5.
18. Kobayashi H, Naito T, Omae K, Omori S, Nakashima K, 
Wakuda K, et al. ILD-NSCLC-GAP index scoring and staging 
system for patients with non-small cell lung cancer and inter-
stitial lung disease. Lung Cancer 2018;121:48-53.
19. Goh NS, Desai SR, Veeraraghavan S, Hansell DM, Copley SJ, 
Maher TM, et al. Interstitial lung disease in systemic scle-
MS Park
328 Tuberc Respir Dis 2020;83:326-328 www.e-trd.org
rosis: a simple staging system. Am J Respir Crit Care Med 
2008;177:1248-54.
20. Volkmann ER, Tashkin DP, Sim M, Li N, Goldmuntz E, Keyes-
Elstein L, et al. Short-term progression of interstitial lung dis-
ease in systemic sclerosis predicts long-term survival in two 
independent clinical trial cohorts. Ann Rheum Dis 2019;78: 
122-30.
21. Goh NS, Hoyles RK, Denton CP, Hansell DM, Renzoni EA, 
Maher TM, et al. Short-term pulmonary function trends are 
predictive of mortality in interstitial lung disease associated 
with systemic sclerosis. Arthritis Rheumatol 2017;69:1670-8.
22. Distler O, Highland KB, Gahlemann M, Azuma A, Fischer A, 
Mayes MD, et al. Nintedanib for systemic sclerosis-associated 
interstitial lung disease. N Engl J Med 2019;380:2518-28.
23. Cottin V, Brown KK. Interstitial lung disease associated with 
systemic sclerosis (SSc-ILD). Respir Res 2019;20:13.
